Figure 1From: Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database Evolution of the total number of patients exposed to Thiazolidinediones (TZD) in France and of the total number of Adverse Drug Reactions (ADR) reported to the French PharmacoVigilance Database in type 2 diabetic patients and in TZD exposed patients.Back to article page